Depemokimab for adults and teens with type 2 asthma
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This study tests a new medicine called depemokimab, given as an injection, to see if it can reduce asthma attacks in people with a specific type of asthma (type 2 high). If you have had asthma for several years and have had recent attacks despite using regular inhalers, this trial might be an option for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 12 years or older.
- You must have had asthma for at least 2 years.
- You must have had at least 2 asthma attacks in the last 3 years, with at least 1 in the past year, despite using regular inhalers.
- You must currently be using a low or medium dose of an inhaled corticosteroid/LABA combination inhaler (like a preventer inhaler).
- You must have signs of type 2 asthma, such as high eosinophils (a type of white blood cell) in your blood, or a high FeNO level, or nasal polyps.
- You must not be a current smoker, ex-smoker with a heavy smoking history, or a vaper.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a new medicine, depemokimab, can help children aged 6 to 11 whose asthma is not well controlled with their current inhalers and who have a type of inflammation called eosinophilic asthma. It may reduce asthma attacks and improve symptoms.
This study tests depemokimab, an injectable biologic, to see how it works in the lungs of people with severe asthma. You would get the drug and have special imaging and a bronchoscopy (a tube with a camera placed into your airways to take tiny tissue samples) so doctors can understand how the medicine reduces inflammation.
This study tests if tezepelumab can help reduce severe asthma attacks in children ages 5 to 11. It compares the drug to a placebo (a dummy treatment) to see if it is safe and effective.
This trial tests a new drug called tozorakimab for adults whose asthma is not well controlled despite using medium-to-high dose inhaled steroids. The study aims to find the best dose and see if it reduces asthma attacks.
This study tests a new inhaler (PT027) against another inhaler (PT007) for teens aged 12 to 17 with asthma. It looks at how well the new inhaler works when used as needed, and if it is safe.
This study tests a new way to monitor severe asthma that is driven by high levels of inflammation (T2-high). It involves a bronchoscopy (a thin tube to look inside your lungs) to see how well the treatment is working.
Hear when a new Asthma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.